leisure time -WSS

leisure time

author：hotspot 2025-09-28 01:36:29 - browse：59957

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

knowledge

WSS

HCA sued by state AG for quality issues at Mission Health

Abortion policy in the spotlight at Republican debate

HCA sued by state AG for quality issues at Mission Health

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Roche's accidental data boosts hopes for anti

FDA advisory panel to debate high blood pressure devices

leisure time

leisure time

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Wegovy improves function in certain heart failure patients

Hollywood unions extend contract negotiations for actors

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Tori Bowie and the unacceptable rates of Black maternal death

Prime Medicine, Myeloid Therapeutics clash over genome

What does generative AI mean for health care? We asked experts

Kellogg’s is going to war over Mexico’s nutrition label rules

Hepatitis C has a cure — but many Americans still lack access to it

Can U.S. cancer drug shortages be fixed?

hotspot

SEC charges former device maker CEO with $41 million fraud

PBMs are inflating the cost of generic drugs. They must be reined in

Roche's accidental data boosts hopes for anti

Vivek Ramaswamy made waves in the debate, much as in biotech

In Spain, a hospital brews its own CAR

Virtual care provider acquires bankrupt Pear's prescription apps

explore

hotspot

knowledge

knowledge